

# IPFA/PEI 23RD INTERNATIONAL WORKSHOP ON “SURVEILLANCE AND SCREENING OF BLOOD BORNE PATHOGENS”




LISBON

IN COLLABORATION WITH INSTITUTO PORTUGUÊS DO SANGUE E DA TRANSPLANTAÇÃO

25-26 MAY 2016

LISBON MARRIOTT HOTEL, LISBON, PORTUGAL



## Workshop Programme

Theme of Meeting: Rationalising Blood Safety Scenarios



## **DAY I – WEDNESDAY 25 MAY 2016**

### **09.00 hrs OPENING SESSION**

- Welcome and Introduction (IPFA/PEI) (5 mins)
- Formal Opening – Official from Portugal MOH (10 mins)
- Presentation from Instituto Português do Sangue e da Transplantação (Portugal) (20 mins)
- Key Note: Anticipating (Re)emerging infections to Ensure Blood Safety – Prof. P. Tiberghien, Etablissement Français du Sang (France) (30 mins)

### **10.15 – 10.45 hrs COFFEE BREAK**

### **10.45 hrs SESSION 2 - PHYLOGENY OF ESTABLISHED BLOOD BORNE VIRUSES**

- Introduction: Basic phylogenetics – Prof. Dr H. Zaaijer, Sanquin Blood-borne Infections (the Netherlands) (20 mins)
- Infected donors: viruses don't lie – Dr T.J.W. van de Laar, Sanquin Blood-borne Infections (the Netherlands) (20 mins)
- Did the donor infect the patient? – Prof. Dr P. Simmonds, University of Edinburgh (United Kingdom) (20 mins)
- Panel Discussion

### **12.15 – 13.45 hrs LUNCH BREAK**

### **13.45 hrs SESSION 3 – ARBOVIRUS TRANSFUSION TRANSMISSION – THE WORLD BEFORE AND AFTER THE CURRENT ZIKV EPIDEMIC**

- KEY NOTE: Epidemiology and Pathogenicity of arbovirus infections, with focus on ZIKV – Dr L.R.P. Petersen, Centers for Disease Control (USA) (30 mins)
- Zika Virus and Blood Safety: Following the Same Path as Chikungunya and Dengue? - Dr D. Musso, Institut Louis Malarde (French Polynesia) (20 mins)
- Phylogeny of dengue, chikungunya and Zika virus strains in donors and transfused patients during a large outbreaks – Dr M. Busch, Blood Systems Research Institute (USA) (20 mins)
- Panel Discussion



**15.15 – 15.45 hrs COFFEE BREAK**

**15.45 hrs SESSION 4 – UNDERSTANDING RESIDUAL VIRAL TRANSMISSION RISK**

- WHO Guideline on Estimation of Residual Risk of HIV, HBV or HCV Infections via Cellular Blood Components and Plasma – Dr M. Nübling, World Health Organisation (Switzerland) (20 mins)
- A new computational strategy for estimating residual viral transmission risk by NAT screened blood components – Dr J. Weusten, Philips Handheld Diagnostics (the Netherlands) (20 mins)
- Impact of changing demographics in the South Africa donor population on HIV transmission risk: A ten year analysis of individual donation NAT screening – Ms M. Vermeulen, South African National Blood Service (South Africa) (20 mins)
- Panel Discussion

**17.15 hrs END OF DAY I**

**19.00 hrs DEPARTURE FOR DINNER**

Kindly sponsored by:



**DAY II – THURSDAY 26 MAY 2016**

**08.30 hrs SESSION 5 – MANUFACTURERS SESSION**

- Abbott Diagnostics
- Cerus
- Roche Molecular Systems
- Grifols

**10.30 – 11.00 hrs COFFEE BREAK**





## 11.00 hrs **SESSION 6 – BEST SCREENING STRATEGIES FOR HEPATITIS B**

- Chronic HBV infection: Time trends and prevalence in world regions – Dr J. Ott, Helmholtz Centre for Infection Research (Germany) (20 mins)
- Adieu HBsAg? - Donor screening strategies in different high/medium/low incidence/prevalence settings – Dr R. Dodd, American Red Cross (USA) (20 mins)
- Japanese experience of HBV Screening – Dr M. Satake, Japanese Red Cross Society (Japan) (20 mins)
- Panel Discussion

## 12.30 – 14.00 hrs **LUNCH BREAK**

Kindly sponsored by:  **GFE Blut**

## 14.00 hrs **SESSION 7 – UPDATE SESSION**

- HEV Update – Blood Components and Plasma Products – Dr D. Domanovic, European Centre for Disease Prevention and Control (Sweden) & Dr B. Flan, LFB Biomedicaments (30 mins)
- The Impact of MSM Policy Changes around the World: what Happened, Why and what Next? – Dr M. Germain, Héma-Québec (Canada) (20 mins)

## 15.00 hrs **SESSION 8 – ALTERNATIVE BLOOD SAFETY STRATEGIES AND IMPACT OF PATHOGEN REDUCTION**

- Bacterial safety of Blood Products: Bacterial Detection and Reduction Technologies – Dr M. Störmer, University Hospital Cologne (Germany) (20 mins)
- Various strategies for reducing viral transmission risk – Dr S. Kleinman, University of British Columbia (Canada) (20 mins)
- Reducing Babesia/Malaria transmission risk – Dr S. Stramer, American Red Cross (USA) (20 mins)
- Evaluating cost effectiveness of alternative blood safety scenarios – Dr B. Custer, Blood Systems Research Institute (USA) (20 mins)
- Panel Discussion

## 16.45 hrs **CLOSURE**

## 17.00 hrs **FAREWELL DRINKS**